Pazopanib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
It is very uncertain whether pazopanib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
It is very uncertain whether pazopanib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).
Pazopanib plus lapatinib showed no clear difference in serious adverse events compared with lapatinib (low certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: haemorrhage compared with lapatinib (very low certainty).
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: thromboembolic events compared with lapatinib (very low certainty).
It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).